Sugi Predict

Sugi Predict / Compounds / SCHEMBL9910075

SCHEMBL9910075

SCHEMBL9910075

CC(C)c1cccc2c1NCCC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 1/20 0.49
▸ GABRA1 P14867 3/20 0.41
▸ GABRG2 P18507 2/20 0.41
▸ GABRB3 P28472 2/20 0.41
▸ GABRB2 P47870 2/20 0.41
▸ TSHR P16473 2/20 0.41
▸ FAAH O00519 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ GABRB1 P18505 1/20 0.41
▸ PTGS1 P23219 1/20 0.41
▸ SLC6A2 P23975 1/20 0.41
▸ HTR2C P28335 1/20 0.41
▸ GABRA5 P31644 1/20 0.41
▸ GABRA3 P34903 1/20 0.41
▸ HTR2B P41595 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9910070 0.89 GABRA1 (0.43) SRCGABRA1GABRG2GABRB3GABRB2
SCHEMBL9564347 0.79 SRC (0.43) SRCLMNATAAR1CXCR4SLC13A5
SCHEMBL11911723 0.79 SRC (0.36) SRCHPGDTAAR1CXCR4KDM4E
SCHEMBL12533360 0.77 SRC (0.35) SRCTAAR1CXCR4
SCHEMBL16746105 0.77 SRC (0.35) SRCTAAR1CXCR4
SCHEMBL27418878 0.77 GABRA1 (0.41) GABRA1GABRG2GABRB3GABRB2TSHR
SCHEMBL11911724 0.77 MAPT (0.36) SRCCA2CYP1A2CYP3A4HPGD
SCHEMBL16398762 0.77 SRC (0.39) SRCCA1CA2LMNATRPV1
SCHEMBL12604283 0.76 PNMT (0.36) SRCCXCR4KDM4EMAPT
SCHEMBL6359546 0.76 SRC (0.53) SRCTSHRCA1CA2HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025918-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-01-25 — — US disclosed
US-20240025918-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-01-25 — — US disclosed
EP-4186896-A1 SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF Betta Pharmaceuticals Co., Ltd (CN) 2023-05-31 — — EP disclosed
US-20220024939-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES RECURIUM IP HOLDINGS, LLC 2022-01-27 — — US disclosed
WO-2021231653-A1 MONO- AND COMBINATION THERAPIES RECURIUM IP HOLDINGS, LLC (US) 2021-11-18 — — WO disclosed
WO-2021127047-A1 COMBINATIONS RECURIUM IP HOLDINGS, LLC (US) 2021-06-24 — — WO disclosed
WO-2021127044-A1 COMBINATIONS RECURIUM IP HOLDINGS, LLC (US) 2021-06-24 — — WO disclosed
WO-2021127039-A1 COMBINATIONS RECURIUM IP HOLDINGS, LLC (US) 2021-06-24 — — WO disclosed
US-20210154188-A1 ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2021-05-27 — — US disclosed
US-20210130473-A1 TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2021-05-06 — — US disclosed
US-20090124612-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
US-20090124612-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
US-20090124609-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
US-20090124609-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 — — US disclosed
US-20080280905-A1 UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS BRISTOL MYERS SQUIBB COMPANY (US) 2008-11-13 — — US disclosed
US-20080280905-A1 UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS BRISTOL MYERS SQUIBB COMPANY (US) 2008-11-13 — — US disclosed
US-7388021-B2 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions BRISTOL MYERS SQUIBB COMPANY (US) 2008-06-17 — — US disclosed
US-7388021-B2 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions BRISTOL MYERS SQUIBB COMPANY (US) 2008-06-17 — — US disclosed
WO-2007139464-A1 ISOINDOLE DERIVATIVES USEFUL FOR TREATING PAIN, GASTROINTESTINAL DISEASES AND CANCER ASTRAZENECA AB (SE) 2007-12-06 — — WO disclosed
EP-0173208-A1 Tetrahydroquinolin-1-yl-carbonyl-imidazole derivatives NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1986-03-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124612-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET SRC 851/4885GABRA1 2292/4885GABRG2 2568/4885
US-20080280905-A1 UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS P2RY1, P2RY11, P2RY2 SRC 2884/4885GABRA1 554/4885GABRG2 1707/4885
US-20220024939-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES MKI67, BRCA1, CCNI SRC 1292/4885GABRA1 3833/4885GABRG2 3451/4885
US-20210130473-A1 TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF TGFBR2, ASGR1, TGFBR1 SRC 1134/4885GABRA1 405/4885GABRG2 221/4885
US-20210154188-A1 ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF ALK, ALKBH5, ALKBH3 SRC 960/4885GABRA1 1521/4885GABRG2 1349/4885
US-20090124609-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET SRC 851/4885GABRA1 2292/4885GABRG2 2568/4885
US-20240025918-A1 KRAS G12D Inhibitors KRAS, NRAS, HRAS SRC 1127/4885GABRA1 3975/4885GABRG2 2978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.